SG Americas Securities LLC Acquires 2,782 Shares of Inogen, Inc. (NASDAQ:INGN)

SG Americas Securities LLC lifted its holdings in shares of Inogen, Inc. (NASDAQ:INGN) by 27.8% in the 4th quarter, HoldingsChannel.com reports. The fund owned 12,782 shares of the medical technology company’s stock after purchasing an additional 2,782 shares during the quarter. SG Americas Securities LLC’s holdings in Inogen were worth $70,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. BlackRock Inc. boosted its stake in shares of Inogen by 5.5% during the 3rd quarter. BlackRock Inc. now owns 3,866,696 shares of the medical technology company’s stock worth $93,883,000 after acquiring an additional 201,073 shares during the period. Vanguard Group Inc. boosted its stake in shares of Inogen by 1.7% during the 1st quarter. Vanguard Group Inc. now owns 2,565,014 shares of the medical technology company’s stock worth $83,157,000 after acquiring an additional 42,755 shares during the period. Fred Alger Management LLC boosted its stake in shares of Inogen by 5.2% during the 4th quarter. Fred Alger Management LLC now owns 1,140,955 shares of the medical technology company’s stock worth $22,488,000 after acquiring an additional 56,711 shares during the period. State Street Corp lifted its holdings in Inogen by 12.4% during the 1st quarter. State Street Corp now owns 1,075,905 shares of the medical technology company’s stock worth $13,427,000 after purchasing an additional 118,605 shares during the last quarter. Finally, Bamco Inc. NY lifted its holdings in Inogen by 2.1% during the 4th quarter. Bamco Inc. NY now owns 976,644 shares of the medical technology company’s stock worth $19,250,000 after purchasing an additional 20,000 shares during the last quarter. 89.94% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. William Blair raised Inogen from a “market perform” rating to an “outperform” rating in a report on Thursday, February 15th. Needham & Company LLC reissued a “hold” rating on shares of Inogen in a report on Tuesday, April 9th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $7.50.

Inogen Price Performance

Shares of NASDAQ INGN opened at $6.75 on Friday. The stock has a market capitalization of $157.48 million, a PE ratio of -1.53 and a beta of 1.06. The business has a fifty day moving average price of $7.63 and a two-hundred day moving average price of $6.29. Inogen, Inc. has a fifty-two week low of $4.13 and a fifty-two week high of $14.10.

Inogen (NASDAQ:INGN) last posted its quarterly earnings results on Tuesday, February 27th. The medical technology company reported ($1.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.49). Inogen had a negative return on equity of 38.98% and a negative net margin of 32.46%. The business had revenue of $75.90 million for the quarter, compared to analyst estimates of $78.09 million. On average, equities analysts expect that Inogen, Inc. will post -2.56 EPS for the current year.

Inogen Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.